Phuturdex › Drugs › Ferric carboxymaltose
Drugs in development · updated 11 November 2026
Ferric carboxymaltose: clinical trials and development status
As of 11 November 2026 Ferric carboxymaltose is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 6 diseases. The most advanced phase is III.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A parenteral iron solution containing ferric iron complexed with carboxymaltose polymers, used in parenteral iron-replacement therapy. Upon administration, ferric carboxymaltose is removed from plasma by the reticuloendothelial system. Subsequently, ferric iron binds to transferrin or is stored as ferritin. Transferrin-bound iron is transported in the plasma to the liver, spleen and bone marrow, where it is incorporated into hemoglobin, and to muscle, where it is incorporated into myoglobin.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Aortic aneurysm | III | 1 | NCT05744219 |
| Iron Deficiencies | II–III | 1 | NCT07217873 |
| Liver neoplasm | III | 1 | NCT05744219 |
| Pancreatic neoplasm | III | 1 | NCT05744219 |
| Scoliosis | II–III | 1 | NCT07217873 |
| Restless legs syndrome | II | 1 | NCT07822607 |
Sites in Europe
2 sites of the active trials in 2 European countries, 1 recruiting.
- France1
- Sweden1
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Ferric carboxymaltose
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.